Chimerix, Inc.’s Post

View organization page for Chimerix, Inc., graphic

4,373 followers

On Saturday, September 23rd at 1:00 pm, please join us in room Grote Zaal for our industry-sponsored session, “H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions,” a one-hour symposium on the diagnosis and treatment of H3 K27M-mutant diffuse glioma, with speakers Dr. Peiter Wesseling (University Medical Center, Amsterdam, NL), Dr. Susan Short (University of Leeds, Leeds, UK), and Dr. Martin van den Bent (Erasmus Medical Center, Rotterdam, NL). #EANO2023

Puja Gupta

LSRP3 @ Stanford University School of Medicine | Research, Medical Science

5mo

I am so unhappy with this inhumane policy of the company that they are not allowing ONC201 as a compassionate drug in India. The patient and family who is already devastated with this diagnosis of High Grade Diffuse Midline Glioma with H3K27M mutation are further tortured to participate in clinical trial by going to a foreign country and staying there for months. At least, for the patients of the countries where there is no clinical trial should be given compassionate drug.

Like
Reply

To view or add a comment, sign in

Explore topics